HighTower Advisors LLC lessened its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 17.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,705 shares of the company's stock after selling 19,840 shares during the period. HighTower Advisors LLC owned about 0.10% of HealthEquity worth $7,422,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in HQY. Holocene Advisors LP bought a new stake in shares of HealthEquity in the 3rd quarter worth $1,246,000. Centiva Capital LP purchased a new position in HealthEquity during the third quarter worth about $366,000. Wasatch Advisors LP grew its position in HealthEquity by 6.6% in the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company's stock worth $635,065,000 after purchasing an additional 483,269 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in HealthEquity in the 3rd quarter valued at about $1,228,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of HealthEquity by 1.9% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 329,477 shares of the company's stock worth $26,968,000 after buying an additional 6,197 shares in the last quarter. Institutional investors own 99.55% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. The Goldman Sachs Group started coverage on HealthEquity in a research report on Friday, November 15th. They set a "neutral" rating and a $108.00 price target for the company. Bank of America raised their target price on HealthEquity from $100.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Mizuho started coverage on shares of HealthEquity in a report on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of HealthEquity from $102.00 to $103.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Finally, Barrington Research boosted their target price on shares of HealthEquity from $105.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, HealthEquity has a consensus rating of "Moderate Buy" and a consensus price target of $110.71.
Read Our Latest Report on HQY
HealthEquity Price Performance
Shares of NASDAQ:HQY traded down $5.61 on Tuesday, hitting $95.39. The company's stock had a trading volume of 1,840,254 shares, compared to its average volume of 633,306. HealthEquity, Inc. has a 1 year low of $62.10 and a 1 year high of $105.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The company has a market capitalization of $8.33 billion, a PE ratio of 79.49, a PEG ratio of 1.57 and a beta of 0.55. The company has a 50-day simple moving average of $93.11 and a 200 day simple moving average of $83.90.
Insider Activity
In other news, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank Corvino sold 1,247 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the transaction, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,536 shares of company stock worth $884,517. 2.20% of the stock is currently owned by insiders.
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
